SciELO - Scientific Electronic Library Online

 
vol.37 número2Efectividad y seguridad de lenalidomida en pacientes con mielofibrosis: serie de casos del programa de uso compasivo españolPermanencia del tratamiento antirretroviral de última generación en la práctica clínica diaria índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Farmacia Hospitalaria

versión On-line ISSN 2171-8695versión impresa ISSN 1130-6343

Resumen

LOPEZ-MONTENEGRO SORIA, Mª Á.; ALBERT MARI, A.  y  JIMENEZ TORRES, N. V.. Measurement of continuous improvement in the safety of oncologic patients. Farm Hosp. [online]. 2013, vol.37, n.2, pp.143-150. ISSN 2171-8695.  https://dx.doi.org/10.7399/FH.2013.37.2.379.

Objective: To analyze continuous improvement in the safety of oncologic patients through the change of quality indicators established with the implementation of a quality management system (QMS) according to the ISO 9001-2008 regulation at a oncologic pharmacy unit (OPU). Method: Prospective and observational study carried out between January of 2008 and December of 2011. The ISO 9001-2008 certification of the OPU included the proceedings of electronic prescription, validation, preparation, delivery, and administration of the antineoplastic therapy. The following quality indicators were established: medication errors (ME), preparation and delivery errors not reaching the patient, and ME reaching the patient. The indicators were calculated quarterly through the Farmis-Oncofarm® software; the adherence standard was defined at < 1 ME per one thousand and the follow-up was done through control graphs. One "postimplementation" period (2008-2011) and one "pre-implementation" period (2007) were established and the U Mann Whitney test was used to compare the median of the indicator for both periods. The differences between the two periods were considered to be statistically significant when the p value was p < 0.05. Results: 140,440 preparations were made at the OPU, for 4,770 patients, corresponding to 52,906 patients-day. The adherence to the standard during the first one-year period allowed reducing the three indicators to < 0,5 ME per one thousand. For preparation ME an abnormal value was identified; the causes were analyzed and improvement measures were proposed. In the post-implementation period, ME were reduced during the post-implementation period as compared to the pre-implementation period (p<0.05). Conclusions: The follow-up of the quality indicators allows measuring and assessing the pharmacotherapy safety in the oncologic patient. After the implementation of the QMS at the OPU, the number of ME has been reduced.

Palabras clave : Patient's safety; Quality indicator; Medication error; Quality standards; Oncology.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons